Press Kit
Salvat at a glance
If you are a media professional and wish to receive more information, please send us an email at media@svt.com.
Salvat’s News and Press kit
Media
Salvat at a glance
Press Kit
What are we doing right now
News
Media
Salvat’s News and Press kit
Media
Salvat at a glance
Press Kit
What are we doing right now
News
Media
Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezSalvat Laboratories, the international company which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients. […]
Salvat, pioneer in using cell-therapy for the treatment of non-consolidated bone fractures (BONECURE project)
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezIt is an innovative project based on pre-differentiated mesenchymal stem cells designed to treat patients with bone consolidation problems post-fracture (atrophic pseudoarthrosis). A Phase II clinical trial has been completed, with very promising results in terms of efficacy and safety, in patients with pseudoarthrosis of long bones. Salvat has invested more than 10 million Euros […]
Salvat plans to launch the first global ocular corticosteroid with nanoemulsion in 2023 for the inflammation and pain after ocular surgery
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezPhase III clinical trials conducted in US confirm that clobetasol is effective and safe in the treatment of inflammation and pain after cataract surgery. The pharmaceutical company has begun the process with health authorities to market the new corticosteroid worldwide by the middle of next year. The company has patented a pioneering technology, IMPACT-SVT®, which […]
Salvat Laboratories enters in the Hong Kong market with its first otic medication
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezSalvat has an agreement with Lee’s Pharmaceutical to distribute the otic treatment Cetraxal Plus in China, Hong Kong and Taiwan. The product has been available in the Spanish market for twenty years and is exported to more than 50 countries. Cetraxal Plus is the only otic treatment in the world that comes in single-dose vials […]
Salvat completes Phase III clinical trials of its new ophthalmic corticosteroid nanoemulsion
/in Salvat International, Salvat Spain, Salvat USA /by Carme LopezThe aim of these trials, which began in 2020, is to prove the efficacy of this innovative drug in treating ocular inflammation and pain after cataract surgery. For the first time in the world, this new product will use nanoparticles applied to the eye in order to help the drug’s absorption and application. With an […]